LGALS3 and Parkinson disease: For example, Gal-3 should be inhibited to treat diseases with chronic onset, such as PD, and be activated to treat acute CNS disorders, such as MCAO, in order to efficiently inhibit the level of inflammation in the CNS and to achieve an optimal therapeutic outcome.